Hospital

Ming-Hei Tai, PharmD, BCOP, shares his concerns about the AQUILA trial and use of daratumumab for smoldering multiple myeloma.

The prevention of preeclampsia may reduce severe maternal morbidity (SMM) risk in pregnant people.

The designation builds on previous regulatory action for ADI-001 and allows for expedited development of the treatment for systemic lupus erythematosus.

Often an indicator of fibrosis or damage to the heart, late gadolinium enhancement was found to be unaffected by the administration of intravenous immunoglobulin (IVIG) in pediatric patients with myocarditis.

The demands of the pharmacy profession—long hours, high stress, and emotional strain—can take a toll on pharmacists’ well-being.

Edward Kim, MD, MBA, discusses critical points of patient leakage in precision medicine, emphasizing the role of multidisciplinary teams in streamlining care, managing medications, and improving patient outcomes.

Ulipristal is a progesterone receptor modulator that prevents pregnancy by blocking the release of an egg from the ovary and inhibiting implantation in the uterus.

The Trop-2-tagreting antibody drug conjugate facilitated improved intracranial penetration with favorable tolerability.

Edward Kim, MD, MBA, highlights the challenges of patient disengagement, data fragmentation, and provider education in precision medicine, emphasizing the need for personalized approaches to enhance patient outcomes, particularly in oncology.

The initiative will provide information about care models for specialists and clinical teams to improve patient outcomes in heart failure.

Encorafenib in combination with cetuximab and mFOLFOX6 met its dual primary end point of overall response rate of 61%.

Diabetic macular edema (DME) is the leading cause of new blindness in the US.

Gold bagging integrates health system-owned specialty pharmacies with clinical workflows to enhance safety, efficiency, outcomes, and patient experience.

The study results build on the “obesity paradox,” which suggests that patients with cancer and obesity have better outcomes.

Nivolumab plus ipilimumab demonstrated a 38% reduction in the risk of disease progression or death.

An inverse relationship was observed between genetic conditions associated with high levels of low-density lipoprotein cholesterol and the risk of developing T2D.

Investigators noted that the differences between the 3 respiratory infections were not as pronounced during the 2023-2024 season.

In the study, 50% of the deaths amongst patients were linked to central nervous system-related causes.

The results highlight hemoglobin A1c/high-density lipoprotein cholesterol as a potential clinical marker for long-term stroke risk.

Some risk factors for chronic kidney disease (CKD) in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) were renal impairment, delayed diagnosis, and hypertension.

Angiotensin receptor neprilysin inhibitors show promise as an alternative to standard management of resistant hypertension.

World Cancer Day, observed annually on February 4th, is a global initiative aimed at raising awareness, reducing stigma, and promoting equitable access to cancer care, with pharmacy professionals playing a vital role in prevention, treatment, and support for patients and communities.

Rising seasonal viruses and emerging concerns emphasize the need for public awareness and prevention.

Sara Rogers, PharmD, discusses the value of the Precision Medicine World Conference 2025 for pharmacy professionals, highlighting key sessions and opportunities aimed to advance precision medicine and pharmacogenomic (PGx) practices.

S-337395 demonstrated an 88.4% reduction in viral load and had a statistically significant improvement in clinical symptoms scores.

Naga Vara Kishore Pillarsetty, PhD, discusses advancements in radiopharmaceuticals for cancer therapy, noting common supply chain challenges, radiation safety measures, and patient misconceptions with the use of these drugs.

Fitusiran is part of a generation of novel RNA interference therapies and is designed for subcutaneous administration for the prophylactic treatment of hemophilia A or B.

The diagnostic identifies patients who may be eligible for treatment with fam-trastuzumab-deruxtecan-nxki (Enhertu; Daiichi-Sankyo, AstraZeneca).

Continuous dosing of ribociclib was associated with better tolerability and outcomes.

Myelofibrosis patients with CALR mutations have lower responses to symptoms and higher rates of anemia after 6 months of therapy with ruxolitinib.